The problem with ROTH coverage, page-4

  1. 1,721 Posts.
    lightbulb Created with Sketch. 40
    Depends on success or failure of VLA's technology. The market is huge for a cancer supplement treatment without the horrific side effects of chemotherapy. $3.84 would be a low mark if this actually works. Still to early to tell. But after 10 years of R&D and trials so far CAVATAK looks very promising.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.